Moneycontrol
Get App
SENSEX NIFTY
you are here:

Jubilant Life Sciences Ltd.

BSE: 530019 | NSE: JUBILANT |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE700A01033 | SECTOR: Pharmaceuticals

BSE Live

Apr 09, 16:00
340.50 16.20 (5.00%)
Volume
AVERAGE VOLUME
5-Day
21,243
10-Day
16,209
30-Day
122,554
14,179
  • Prev. Close

    324.30

  • Open Price

    340.50

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Apr 09, 15:56
341.35 16.25 (5.00%)
Volume
AVERAGE VOLUME
5-Day
289,802
10-Day
326,259
30-Day
274,313
179,293
  • Prev. Close

    325.10

  • Open Price

    341.35

  • Bid Price (Qty.)

    341.35 (3840)

  • Offer Price (Qty.)

    0.00 (0)

ANNOUNCEMENTS ON Jubilant Life

  • Apr 08, 2020 12:39 Source: BSE

    Jubilant Life Sciences - Undertaking Under Regulation 57(2) Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015

    Dear Sirs, We refer to our letter dated January 8, 2020 intimating that the Company has redeemed the outstanding Non-Convertible Debentures alongwith accrued interest thereon on January 7, 2020. Pursuant to the provisions of Regulation 57(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has provided all the documents and intimations required to be submitted to the Debenture Trustee i.e. Vistra ITCL (India) Limited during the Financial Year 2019-20 in terms of the Debenture Trust Deeds and the SEBI (Issue and Listing of Debt Securities) Regulations, 2008. This is for your information and records.

  • Mar 31, 2020 22:11 Source: BSE

    Jubilant Life Sciences - Schedule Of Investor Conference Call For Jubilant Life Sciences Limited - Update On Company'S Position With Respect To COVID-19 Pandemic

    Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on April 1, 2020 at 5.00 p.m. to update the Company''s position with respect to COVID-19 pandemic. Details of the Conference Call are attached. This is for information and record.

  • Mar 31, 2020 16:24 Source: BSE

    Jubilant Life Sciences - Jubilant Receives EIR From USFDA For Its Solid Dosage Facility At Salisbury, Maryland USA

    Dear Sirs, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a communication pertaining to USFDA inspection. We request you to take the same on record.

  • Mar 31, 2020 15:50 Source: BSE

    Jubilant Life Sciences - Jubilant Life Sciences Ltd reply to clarification sought by the exchange

    The Exchange had sought clarification from Jubilant Life Sciences Ltd with respect to news article appearing on zeebiz.com March 30, 2020 titled "Jubilant Life Sciences hit by coronavirus; Nanjangud plant API production shut".Jubilant Life Sciences Ltd response is enclosed.

  • Mar 31, 2020 7:49 Source: BSE

    Jubilant Life Sciences - Clarification sought from Jubilant Life Sciences Ltd

    The Exchange has sought clarification from Jubilant Life Sciences Ltd with respect to news article appearing on zeebiz.com March 30, 2020 titled "Jubilant Life Sciences hit by coronavirus; Nanjangud plant API production shut".The reply is awaited.

  • Mar 24, 2020 17:14 Source: BSE

    Jubilant Life Sciences - Closure of Trading Window

    Pursuant to the Company''s Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company will be closed for ''Designated Persons'' from Wednesday, March 25, 2020 and the same shall remain closed till 48 hours after announcement of the financial results for the quarter and year ending March 31, 2020 to the Stock Exchanges. Accordingly, the Designated Persons have been intimated not to trade in the securities of the Company during the aforesaid period of closure of Trading Window. This is for your information and records.

  • Mar 19, 2020 12:25 Source: BSE

    Jubilant Life Sciences - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for East Bridge Capital Master Fund Ltd & East Bridge Capital Master Fund I Ltd

  • Feb 28, 2020 11:29 Source: BSE

    Jubilant Life Sciences - Fixes Record Date for Interim Dividend

    Jubilant Life Sciences Ltd has informed BSE that the Company has fixed March 11, 2020 as the Record Date for the purpose of Payment of Interim Dividend.The interim dividend will be paid / despatched on or before March 27, 2020.

  • Feb 27, 2020 13:09 Source: NSE

    Jubilant Life Sciences Limited

    Jubilant Life Sciences Limited has informed the Exchange that the Company has fixed Record Date as March 11, 2020 for the purpose of Interim dividend

  • Feb 27, 2020 13:09 Source: NSE

    Jubilant Life Sciences Limited

    Jubilant Life Sciences Limited has informed the Exchange that the Board of Directors has, at its meeting held February 27, 2020, declared interim dividend @ 500% i.e. Rs. 5 per Equity Share of Re. 1 each on the paid-up Equity Share capital of the Company for the Financial Year 2019-20.

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Feb 27, 2020
Remark : Interim Dividend